01. Doctor Overview
Dr. Umut Sarpel is a board-certified surgical oncologist working at The Mount Sinai Medical Center. She is also an Associate Professor of Surgery and an Associate Professor of Medical Education at Mount Sinai. She has won multiple awards for her dedication to teaching and written chapters for textbooks. She is also the sole author of one textbook.
In addition to her medical degree, Dr. Sarpel also completed an additional two years of specialty training in surgical oncology and earned a Master of Science in clinical research. She continues research at Mount Sinai, where she focuses her efforts on the study of cancer and the liver.
In addition to her research, Dr. Sarpel also advocates for healthcare equity. Her work in the area of healthcare disparities earned her a National Cancer Institute grant. She intends to use this grant to investigate the disparities in the treatment of hepatocellular carcinoma.
In her practice, Dr. Sarpel specializes in patients suffering from cancer. She works specifically with patients diagnosed with cancers of the stomach, pancreas, liver, biliary tree, small bowel, colon and sarcomas.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Surgical Oncology
Other Interests & Specialties: Heated intraperitoneal chemotherapy (HIPEC), open and laparoscopic surgery, robotic surgery, abdominal surgery, hepatobiliary surgery and cancer.
Certifications, Awards & Accolades: American Board of Surgery Certification, Fellow of the American College of Surgeons, member of the Society of Surgical Oncology, member of the American HepatoPancreatoBiliary Association, member of the International Liver Cancer Association, Medical Student Teaching Award in Surgery, the House Staff Award for Excellence in Teaching and the Humanism, Excellence in Teaching Award
Education & Experience:
- Medical Degree from SUNY Buffalo – School of Medicine & Biomedical Sciences
- Residency in General Surgery at Mount Sinai Hospital
- Fellowship in Surgical Oncology at Mount Sinai Hospital
Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival. Journal of Surgical Oncology. May 2019; 119(6):758-765. doi: 10.1002/jso.25379
Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C. Annals of Surgical Oncology. December 2017; 24(13):3831-3836. doi: 10.1245/s10434-017-6112-z
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with epithelial appendiceal neoplasms. International Journal of Hyperthermia. May 2016; 32(3):311-5. doi: 10.3109/02656736.2016.1152514